Synovial Sarcoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Synovial Sarcoma Epidemiology Forecast Report Coverage

Expert Market Research's “Synovial Sarcoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of synovial sarcoma. It projects the future incidence and prevalence rates of synovial sarcoma cases across various populations. The study covers age, gender, and type as major determinants of the synovial sarcoma population. The report highlights patterns in the prevalence of synovial sarcoma over time and projects future trends based on multiple variables.

Synovial Sarcoma Understanding: Disease Overview

Synovial sarcoma is a rare and aggressive type of soft tissue sarcoma that typically arises near joints, tendons, or bursae, most commonly in the arms and legs. Despite its name, it does not originate from synovial tissue. It primarily affects adolescents and young adults, with a peak incidence between 15 and 40 years of age. The tumor is characterized by a specific chromosomal translocation, t(X;18), which serves as a key diagnostic marker. Due to its slow-growing nature, synovial sarcoma is often diagnosed at an advanced stage, requiring multimodal treatment.

Synovial Sarcoma Epidemiology Perspective

The synovial sarcoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for synovial sarcoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for synovial sarcoma and their trends. The synovial sarcoma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The age‑adjusted incidence of synovial sarcoma in the U.S. was 0.15 per 100,000 from 2000–2020, according to SEER data, equating to about 580 new cases annually, with a 5‑year prevalence of 0.56 per 100,000 and 62.9% overall survival. Younger adults, particularly those aged 20-49, are most frequently affected.
• As reported in a 2023 SEER-based analysis, synovial sarcoma accounts for 5-10% of all soft tissue sarcomas in Western Europe, which had an adjusted STS incidence of 2.41 per 100,000 in 2021. This translates to a regional synovial sarcoma incidence of approximately 0.12-0.24 per 100,000.
• Lower extremity is the most frequent primary site (0.07 per 100,000), with superior survival in upper extremity tumors but significantly worse outcomes (5-year OS 26%) for intrathoracic cases.
• Analysis from SEER reveals histological subtypes greatly influence survival: 5/10‑year survival rates are biphasic (69%/60%), monophasic (59%/49%), and epithelioid (32%/26%)

Read more about this report - Request a Free Sample

Country-wise Synovial Sarcoma Epidemiology Segment

The synovial sarcoma epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, synovial sarcoma remains a rare but serious soft tissue malignancy, with an age-adjusted incidence of approximately 0.15 per 100,000 and a five-year prevalence close to 0.56 per 100,000. Italy demonstrates a comparable disease burden, aligning with detection trends seen in other developed nations. In the United Kingdom, synovial sarcoma continues to be monitored under national sarcoma initiatives, aiding early diagnosis and specialist care. Meanwhile, synovial sarcoma accounts for 19.2% of translocation-related sarcomas in Japan, with 5-year survival exceeding 70% in localized cases, reflecting promising prognosis with timely, multimodal treatment.

Synovial Sarcoma: Treatment Overview

The treatment of synovial sarcoma typically involves a multimodal approach to improve survival and minimize recurrence. Surgical resection with wide margins is the cornerstone, aiming for complete tumor removal. Radiation therapy is commonly used pre- or post-operatively to enhance local control, particularly in high-grade or inoperable tumors. Chemotherapy, often with agents like ifosfamide and doxorubicin, is considered in advanced, metastatic, or high-risk cases. Targeted therapies, such as pazopanib, have shown benefit in metastatic or refractory cases. Clinical trials and immunotherapies are emerging for resistant or relapsed disease, particularly those targeting NY-ESO-1 antigens expressed in synovial sarcoma.

Key Questions Answered

• What are the key findings of synovial sarcoma epidemiology in the 8 major markets?
• What will be the total number of patients with synovial sarcoma across the 8 major markets during the forecast period?
• What was the country-wise synovial sarcoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of synovial sarcoma patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of synovial sarcoma during the forecast period of 2026-2035?
• What are the currently available treatments for synovial sarcoma?
• What are the disease risks, signs, symptoms, and unmet needs of synovial sarcoma?

Scope of the Synovial Sarcoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of synovial sarcoma based on several factors.
• Synovial Sarcoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The synovial sarcoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Soft Tissue Sarcoma Market Report

Global Oncology Drugs Market